RELIEF closes CHF 10m private placement: the advisors
RELIEF THERAPEUTICS Holding AG, a biopharmaceutical company with its lead compound RLF-100TM (Aviptadil) in advanced clinical development to treat severe COVID-19 patients, has entered into a binding agreement with a single healthcare-dedicated U.S. institutional investor to purchase in a private placement Relief shares of CHF 10m, to be delivered from Relief’s treasury shares that were issued out of its authorized share capital under exclusion of the existing shareholders’ pre-emptive rights. The transaction closed on 18 March 2021. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.
